Palatin net loss narrows to $8.38 million in FY26; revenue turns to $13.19 million
Bitget2026/09/28 11:31- Palatin posted a net loss of $8.38 million, narrowing from $17.31 million a year earlier.
- Loss per share improved to $2.96 from $32.15 in the prior fiscal year.
- Revenue was $13.19 million versus no revenue a year earlier, including $9.4 million tied to Boehringer Ingelheim.
- Cash and cash equivalents rose to $7.49 million from $2.56 million at June 30, 2025; it flagged a need for additional funding.
- Phase 1 SAD/MAD for a once-weekly injectable MC4R peptide is targeted for 1H 2027, with initial data targeted in 2H 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
CNN Enters Generative AI Partnership with Google
US Stock Market Movement | Nvidia-backed AI pharmaceutical company Iambic Therapeutics (IAM.US) debuts on Nasdaq, surging over 11% after opening
As of press time, the stock is up more than 11%, trading at $17.77.
US Stock Market Movement | 3D Printing Materials Supplier Amaero (AMRO.US) Debuts on US Stock Market, Trading Halt Triggered After Opening
Amaero, a manufacturer specializing in titanium and refractory metal powders for 3D printing in the defense and aerospace sectors, has gone public on the US stock market.
Crypto prices
More
